Third Quarter Financial Highlights: Total revenues decreased $17.4 million year over year to $448.8 million Construction Equipment and Material Handling […]
Advancing investigation of [212Pb]VMT01 as a monotherapy and in combination with the anti-PD-1 antibody, nivolumab, in patients with previously treated […]
Sequential Revenue Growth of 33% Quarter-Over-Quarter Adjusted EBITDA Growth of 255% to $0.2 million1Year-Over-Year, at 2% Margin1 Net Income Growth of […]